ViV TAVR with 26mm Evolut FX Valve in Degenerated Surgical Valve After Valve Fracture – September 2022

Case & Plan: 77-year-old male presents with worsening lightheadedness and dyspnea on exertion. Past medical history is significant for hypertension, hyperlipidemia, non-obstructive CAD, AF, prior stroke with left sided weakness, s/p bioprosthetic aortic valve replacement in 2008 and H/o bladder cancer s/p resection (2018), stomach cancer s/p partial gastrectomy (2010) & prostate cancer s/p brachytherapy (2007). A recent echocardiogram revealed severe bioprosthetic AS/AR of prior 25mm Mosaic valve (PG/MG/PV: 67/42/4.1), mild MR, mild TR and LVEF 65%. CTA measurement revealed patient to be suitable for transfemoral (TF) valve-in-valve TAVR. The patient’s STS PROM risk for redo SAVR is 1.9%. Heart team evaluation deemed the patient at high risk for redo surgery and appropriate for TF TAVR. Now planned for TF valve-in-valve (ViV) TAVR via right percutaneous femoral arterial access using 26mm Evolut FX valve after balloon valve fracture using a 24mm True Balloon, with Sentinel cerebral embolic protection.

Comments

Leave a Reply

Your email address will not be published.*

Yes, I would like to receive emails from Mount Sinai Hospital. Sign me up!


By submitting this form, you are consenting to receive marketing emails from: Mount Sinai Hospital, One Gustave L. Levy Place, Box, New York, NY, 10029, https://ccclivecases.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact